Mario Tama/Getty Images News Quick Background If you're like me at all, you enjoy being a stock picking voyeur. What I mean is that it's both interesting and fun to listen to someone explain their stock picks. This is especially enjoyable as a fly on the wall, where you don't necessarily have to interact or explain anything. Then again, it can be very enjoyable to respond, criticize, or agree. That's what's great about articles like this one. That said, I'll be talking about Johnson & Johnson (JNJ). I'm ...

When a stock soars in the triple digits in a short period of time, it attracts everyone's attention. And if you've invested a lot in that particular player, you could get rich overnight. That sounds wonderful, but in reality, most wealth-building stories happen over a period of years, thanks to investing in rather average stocks.By average, I mean companies that aren't necessarily developing a new cutting-edge technology or growing earnings in leaps and bounds. Instead, I'm talking about players that have s ...

Johnson & Johnson (JNJ) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Shares of this world's biggest maker of health care products have returned +2.7% over the past month versus the Zacks S&P 500 composite's +3.5% change. The Zacks Large Cap Pharmaceuticals industry, to which Johnson & Johnson belongs, has gained 8.6% over this period. Now the key question is: Where could the stock b ...

Coca-Cola and Other Dividend Kings That Have Raised Their Payouts for 60 Years or More ...

Johnson & Johnson (JNJ) closed the most recent trading day at $161.63, moving +0.06% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 0.15%. On the other hand, the Dow registered a loss of 0.42%, and the technology-centric Nasdaq increased by 0.09%.Prior to today's trading, shares of the world's biggest maker of health care products had gained 4.17% over the past month. This has lagged the Medical sector's gain of 6.58% and outpaced the S&P 500's gain of 3. ...

Johnson & Johnson. (NYSE:JNJ) J.P. Morgan 42nd Annual Healthcare Conference January 8, 2024 12:45 PM ET Company Participants Joaquin Duato - Chairman and CEO of J&J Conference Call Participants Chris Schott - JPMorgan Chris Schott Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting this fireside discussion today with Joaquin Duato, Chairman and CEO of J&J. So, Joaquin, Happy New Year. Great speaking with you today. I thought it might be a good way to start the conversat ...

Johnson & Johnson. (NYSE:JNJ) J.P. Morgan 42nd Annual Healthcare Conference January 8, 2024 12:45 PM ET Company Participants Joaquin Duato - Chairman and CEO of J&J Conference Call Participants Chris Schott - JPMorgan Chris Schott Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting this fireside discussion today with Joaquin Duato, Chairman and CEO of J&J. So, Joaquin, Happy New Year. Great speaking with you today. I thought it might be a good way to start the conversat ...

Key TakeawaysJohnson & Johnson said Monday that it bought Ambrx Biopharma for about $2 billion to boost its oncology portfolio.The $28-per-share all-cash offer is at a 105% premium to Ambrx's closing price on Friday.Ambrx's clinical and preclinical treatments use antibody drug coagulates to attack a variety of cancer cells.Ambrx shares more than doubled following the news, hitting an all-time high.Ambrx Biopharma Inc. (AMAM) shares more than doubled Monday on news that Johnson & Johnson (J&J) (JNJ) would pu ...

ToplineJohnson & Johnson will pay an estimated $700 million to resolve an investigation by more than 40 states into the pharmaceutical firm’s marketing of its talcum powder, according to Bloomberg, following thousands of lawsuits alleging it failed to warn customers about cancer risks.The pharmaceutical firm faces thousands of lawsuits alleging its talcum powder poses cancer risks. Getty Images Key FactsThe tentative agreement will end an ongoing probe into Johnson & Johnson’s talcum-based baby powder and w ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...